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TSC on the endocrine system are not yet understood,9 
and TSC might cause amenorrhea independently. This 
relationship needs to be assessed. 
Finally, the authors mention the beneﬁ ts of oral 
mTOR inhibitors for patients with TSC that are 
not addressed by this analysis. mTOR inhibitors 
are eﬃ  cacious for renal angiomyolipomas and 
lymphangioleimyomatosis,10,11 and there are continuing 
and completed studies in patients with TSC to assess 
oral mTOR inhibitors for intractable epilepsy (EXIST-3; 
NCT01713946) and cognition (TRON; NCT01954693) 
and topical mTOR inhibitors for disﬁ guring facial 
angioﬁ bromas (TREATMENT; NCT01526356). Surgical 
interventions for SEGAs do not oﬀ er these positive side-
eﬀ ects in the rest of the body. With the recent promise 
shown by mTOR inhibitors to help neural connectivity 
and the fairly minor negative side-eﬀ ect proﬁ le, the 
drugs might soon be prescribed to patients with TSC 
for indications other than tumour shrinkage. The mTOR 
inhibitor revolution rolls on…  
Hope Northrup
Division of Medical Genetics, Department of Pediatrics, The 
University of Texas Medical School at Houston, Houston, 
TX 77030, USA
hope.northrup@uth.tmc.edu
Chromoplexy and hypoxic microenvironment drives 
prostate cancer 
In The Lancet Oncology, Emilie Lalonde and colleagues’ 
retrospective cohort analysis1 assesses genomics, 
genomic instability, and hypoxia as predictors of 
recurrence in men with localised prostate cancer. 
Recurrence was measured mainly on the basis of 
recurrence and progression of prostate-speciﬁ c antigen 
by standard deﬁ nitions after either radiotherapy or 
surgery. The investigators controlled for pretreatment 
prostate-speciﬁ c antigen, Gleason score, and T stage.
Their results suggest that genomic signatures or 
measures of genomic instability have independent 
value in prediction of biochemical (prostate-speciﬁ c 
antigen) relapse and clinical metastasis in patients 
with localised prostate cancer. The addition of tumour 
hypoxia measures to genomic data reﬁ ned prediction of 
recurrence when the investigators controlled for clinical 
covariates. Hypoxia was not associated with a speciﬁ c 
genomic signature, suggesting that it is caused by 
epigenetic factors that determine the microenvironment 
of a tumour. Although the mechanisms by which hypoxia 
leads to radiation resistance can be reasonably assumed, 
the mechanism for an association between hypoxia in 
tumour tissue and biochemical recurrence after surgery 
is far less clear. Genetic aberrations driving both hypoxia 
and cancer progression could be an explanation, but in 
this study there was no association between genomic 
alterations and hypoxia. As such, the work in Lalonde 
and colleagues’ study is novel in that it shows that cancer 
aggression is driven not only by genome instability and 
mutations, but also by tissue hypoxia.
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The eﬀ ectiveness of radiation is very dependent on the 
oxygen status of the tissue being treated, with tumour 
sensitivity increased by a factor of about 3 in normoxic 
compared with hypoxic tumours. A rapid increase in 
radiosensitivity happens as the oxygen concentration 
reaches 30 mm Hg or 0·5% oxygen.2 Studies of patients 
with cervical cancer and soft-tissue sarcoma treated 
with radiation have shown that hypoxic tumours are 
more likely to recur and metastasize than are normoxic 
tumours.3,4 A series of interventions to improve tumour 
oxygenation have been attempted in order to improve 
radiotherapy eﬃ  cacy. These interventions are divided 
into three categories: ﬁ rst, increased oxygen delivery by 
the blood (hyperbaric oxygen, breathing carbogen [a 
mixture of oxygen and carbon dioxide], nicotinamide, 
blood transfusions, and erythropoietin), second, 
oxygen mimetics used in the radiochemical process 
(nitroimidazoles), and, third, destruction of hypoxic cells 
(hypoxic cytotoxins and hyperthermia).5 
In a meta-analysis5 of more than 10 000 patients 
with solid tumors (including bladder, uterine cervix, 
head and neck, brain, lung, oesophagus, and pancreas) 
from 86 clinical trials using hyperbaric oxygen, 
chemical sensitizers, carbogen breathing, and blood 
transfusions, the investigators reported a signiﬁ cant 
improvement in locoregional control (odds ratio [OR] 
0·77, 95% CI 0·71–0·86) and a signiﬁ cant survival 
beneﬁ t (0·87, 0·81–0·95) with hypoxic modiﬁ ers. Use 
of hyperbaric oxygen was more beneﬁ cial than other 
hypoxic modiﬁ cations. Despite these ﬁ ndings, hypoxia 
modiﬁ cation is not used on a routine basis clinically and 
should be further explored. 
In terms of genomic signatures, Lalonde and 
colleagues provide strong evidence that links diﬀ erences 
in the prostate cancer genome with clinical outcomes. 
Identiﬁ cation of a DNA signature that robustly predicts 
biochemical recurrence represents a great stride in the 
molecular characterisation of prostate cancer. Not only 
was the 100-loci signature independently prognostic, 
but it also outperformed all published RNA signatures. 
DNA signatures are likely to be more consistent than 
are those generated from RNA expression, because of 
transcriptional heterogeneity and epigenetic eﬀ ects. 
Notably, Lalonde and colleagues’ ﬁ ndings show that the 
combination of percentage of genome alteration and 
hypoxia selects a group of about 25% of low-risk men 
with prostate cancer who are likely to have biochemical 
failure before 18 months. In the context of management 
of clinical prostate cancer, this DNA–hypoxia signature 
for pretreatment stratiﬁ cation might become especially 
useful for enabling of active surveillance strategies. With 
validation in an active surveillance population, a so-
called quiet genomic or hypoxic subtype could be added 
to criteria, thus enabling patients who are classiﬁ ed 
as high risk on the basis of genomic categorisation to 
receive upfront treatment while allowing the quiet 
group to avoid intervention. The potential of the speciﬁ c 
methodology described by Lalonde and coleagues will 
need to be compared with other gene signatures in 
development and use.6 
Genomic instability is an evolving concept in clinical 
cancer. Chromoplexy, or chromosomal change, in which 
the prostate cancer tumour genome advances through 
mutation, translocation, and other interdependent 
DNA rearrangements mediated by post-translational 
modiﬁ cations such as ubiquitination and sumoylation, 
might be key to a series of essential cancer processes 
including avoidance of apoptosis, invasion, and 
metastasis, and therapeutic resistance.7 Hence, measures 
of genomic heterogeneity, instability or change 
might better characterise the notion of chromoplexy 
as a measure of cancer cells or clusters to achieve key 
biological functions needed for tumour progression 
compared with individual genetic aberrations or 
disordered pathway signaling. 
Findings in Lalonde and colleagues’ study related to 
risk strata need prospective validation in other cohorts. 
Although still strictly hypothesis-generating, risk strata 
are not only an important biological accomplishment, 
but might also have therapeutic implications. 
Actionable mutations can be targeted while hypoxia 
might be modulated in various ways, each with the goal 
of improving response and outcome. Much work still 
needs to be done to formulate the best combination of 
targeted therapy for the cancer cell and modiﬁ cation of 
the microenvironment to optimise some of our oldest 
therapies, including radiation. 
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Breast cancer is the most common cause of cancer 
deaths for women worldwide.1 The number of women 
with breast cancer in low-income and middle-
income regions is increasing over time.2 Important 
advances for eﬀ ective breast cancer management 
have mainly beneﬁ ted high-income countries. In 
such countries, evidence-based guidelines outlining 
optimum approaches for early detection, diagnosis, 
and treatment of breast cancer have been implemented 
in national cancer control programmes.3 Poor health-
care resources and poorly organised health-care 
systems, however, represent a substantial barrier to 
the implementation of such practices in low-to-middle 
income countries (LMICs).4 
The Breast Health Global Initiative (BHGI) developed 
practical guidelines for breast cancer control that are 
evidence-based, resource stratiﬁ ed, and culturally 
appropriate, with the aim of integrating practices in 
early detection, diagnosis, and treatment for breast 
cancer into existing health-care systems in LMICs. 
Since 2002, the BHGI has held a series of international 
summits that have brought together experts from 
around the world to develop consensus panels to devise 
appropriate resource-stratiﬁ ed guidelines for breast 
cancer care and management.
We examined the literature systematically to assess 
implementation of BHGI guidelines from the creation 
of knowledge in guideline development, through 
guideline dissemination in the global health published 
work, and organisational adoption and implementation 
of the guidelines. The search identiﬁ ed 2097 articles, of 
which 1033 were duplicates, and 288 documents were 
not relevant to BHGI. Of the 776 remaining articles, 
224 (29%) were direct products of the BHGI group and 
authors and were not included in our analysis. The ﬁ nal 
sample consisted of 552 articles. 
The BHGI guidelines have been increasingly referenced 
in global health literature (ﬁ gure). Of the 552 unique 
articles citing the BHGI guidelines, 359 (65%) referenced 
either the guidelines’ overviews (200 [36%]) or the 
early detection guidelines (159 [29%]). The remaining 
guideline topics were cited less frequently: breast 
cancer diagnosis (52 [9%]), treatment (84 [15%]), 
and the changes needed to the health-care systems 
(48 [9%]). Health-care system guidelines were 
increasingly referenced over time, and by 2011, 
exceeded the articles referencing diagnostic guidelines. 
Of the 552 documents, 283 (51%) focused on LMICs 
in sub-Saharan Africa (77 [14%]), Asia (71 [13%]), Latin 
America (71 [13%]), and the Middle East (50 [9%]). 
Another 181 (33%) articles were non-country speciﬁ c, 
and the remainder came from HICs. On the basis of the 
citation analysis, 375 (68%) cited BHGI guidelines as a 
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Figure: Frequency of articles referencing the Breast Health Global Initiative guidelines, by year of 
publication (n=552)
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